Status: Recruiting
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chongqing Precision Biotech Co., LtdUpdated: Nov 15, 2024Locations: 1
Eligibility criteria
Patients of any gender, aged between 18 and 75 years (inclusive); [+10]
Presence of active central nervous system invasion during screening; [+12]